NICE recommends ustekinumab

The U.K.'s NICE issued a final appraisal determination recommending use of Stelara ustekinumab from Johnson & Johnson (NYSE:JNJ) to treat plaque psoriasis in adults where the disease is severe as defined by a total PASI of 10 or more and a Dermatology Life Quality Index of more than 10. The recommendation also is limited to those who have failed to respond to standard systemic therapies such as cyclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet radiation), or patients who are intolerant of or have a contraindication to these treatments. The guidance reiterates a preliminary appraisal issued in May (See BioCentury Extra, Wednesday, May 20, 2009).

The recommendation also is contingent upon J&J providing the 90 mg dose (two 45 mg vials) for people who weigh more than 100 kg at the cost of a single vial. The appeal period ends on Aug. 28. The guidance can be found at http://www.nice.org.uk/nicemedia/pdf/PsoriasisUstekinumabFAD.pdf ...